Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs

Current Medicinal Chemistry

Volumn 17, Issue 30, 2010, Pages 3514-3532

  Durdagi, S ^a   Subbotina, J ^a   Lees Mille, J ^b   Guo, J ^b   Duff, H J ^b   Noskov, S Y ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

Author keywords

Biological channels; Blockers and activators of herg; Channel activation and blockade; Herg; Herg screening; Long qt syndrome; Potent modeling strategies of ion channels

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; A 935142; AMIODARONE; BEPRIDIL; CISAPRIDE; CLOFILIUM; DOFETILIDE; DOMPERIDONE; DRONEDARONE; DROPERIDOL; GREPAFLOXACIN; HALOPERIDOL; IBUTILIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NIFLUMIC ACID; NS 1643; NS 3623; PD 118057; PD 307243; PIPERANOMETOZINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG1; POTASSIUM CHANNEL STIMULATING AGENT; PROPAFENONE; RETIGABINE; RPR 260243; SERTINDOLE; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOXAZOLAMINE;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG MECHANISM; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; POTASSIUM CURRENT; Q WAVE; SUDDEN DEATH; T WAVE; TACHYCARDIA;

ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; POTASSIUM CHANNEL BLOCKERS; PROTEIN STRUCTURE, TERTIARY;

EID: 77957938332     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792927886     Document Type: Article

References (179)

1. Du, L.; Li, M.; You, Q. The interactions between hERG potassium channel and blockers. Curr. Top Med. Chem. 2009, 9, 330-338.
2. Diller, D.J. In Silico hERG Modeling: Challenges and Progress. Curr. Comp. Aided Drug Des. 2009, 5, 106-121.
3. Mitcheson, J.S.; Perry, M.D. Molecular determinants of highaffinity drug binding to HERG channels. Curr. Opin. Drug Dis. Develop. 2003, 6, 667-674.
4. Sanguinetti, M.C.; Jiang, C.; Curran, M.E.; Keating, M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81, 299-307.
5. + channel: target and antitarget strategies in drug development. Pharmacol. Res. 2008, 57, 181-195.
6. Wang, Z. Potassium channels: Oncogenic potential and therapeutic target for cancers. Top. Med. Chem. 2008, 3, 55-89.
7. Fermini, B. Recent Advances in Ion Channel Screening Technologies. Top. Med. Chem. 2008, 3, 1-25
8. Duff, H.J. hERG: the long and short of it. Heart Rhythm 2008, 5(4), 591-592.
9. Perrin, M.J.; Subbiah, R.N.; Vandenberg, J.I.; Hill, A.P. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction Progr. Biophys. Mol. Biol. 2008, 98, 137-148.
10. Abbott, G.W.; Xu, X.; Roepke, T.K. Impact of ancillary subunits on ventricular repolarization. J. Electrocardiol. 2007, 40, S42-S46
11. Hancox, J.C.; McPate, M.J.; El Harchi, A.; Zhang, Y.H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Therap. 2008, 119, 118-132.
12. + channel S5P extracellular linker: Role of an amphipathic alphahelix in c-type inactivation. J. Biol. Chem. 2003, 278, 4213642148.
13. Curran, M.E.; Splawski, I.; Timothy, K.W.; Vincent, G.M.; Green, E.D.; Keating, M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80, 795803.
14. Imai, Y.M.; Ryu, S.; Oiki, S. Docking model of drug binding to the human ether-a-go-go potassium channel guided by tandem dimer mutant patch-clamp data: A synergic approach. J. Med. Chem. 2009, 52, 1630-1638.
15. Song, M.; Clark, M. Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model. 2006, 46, 392-400.
16. Dubus, E.; Ijjaali, I.; Petitet, F.; Michel, A. In silico classification of hERG channel blockers: a knowledge-based strategy. ChemMedChem 2006, 1, 622-630.
17. Masetti, M.; Cavalli, A.; Recanatini, M. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies. J. Comput. Chem. 2008, 29, 795-808.
18. + channel blockers. Eur. J. Med. Chem. 2009, 44, 1926-1932.
19. Priest, B.T.; Bell, I.M.; Garcia, M.L. Role of hERG potassium channel assays in drug development. Channels, 2008, 2, 87-93.
20. Warmke, J.W.; Ganetzky, B. A family of potassium channel genes related to eag in Drophila and mammals. Proc. Natl. Acad. Sci. 1994, 91, 3438-3442.
21. Farrelly, A.M.; Ro, S.; Callaghan, B.P.; Khoyi, M.A.; Fleming, N.; Horowitz, B.; Sanders, K.M.; Keef, K.D. Expression and function of KCNH2 (HERG) in the human jejunum. Am. J. Pysiol. Gastrointest. Liver Physiol. 2003, 284, 883-895.
22. Ashcroft, F.M. Ion Channels and Disease: Channelopathies, Academic Press, San Diego, 2000.
23. Shieh, C.C.; Coghlan, M.; Sullivan, J. P.; Gopalakrishnan, M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev. 2000, 52, 557-593.
24. Lehmann-Horn, F.; Jurkat-Rott, K. Voltage-gated ion channels and hereditary disease. Physiol. Rev. 1999, 78, 1317-1372.
25. Seebohm, G. Activators of Cation Channels: Potential in Treatment of Channelopathies. Mol. Pharmacol. 2005, 67, 585-588.
26. Derst, C.; Konrad, M.; Kockerling, A.; Karolyi, L.; Deschenes, G.; Daut, J.; Karschin, A.; Seyberth, H.W. Mutations in the ROMK gene in antenatal Bartter syndrome are associated with impaired K+ channel function. Biochem. Biophys. Res. Commun. 1997, 230, 641-645.
27. Thomas, P.M.; Cote, G.J.; Wohllk, N.; Haddad, B.; Mathew, P.M.; Rabl, W.; Aguilar-Bryan, L.; Gagel, R.F.; Bryan, J. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995, 268, 426-429.
28. Nestorowicz, A.; Wilson, B.A.; Schoor, K.P.; Inoue, H.; Glaser, B.; Landau, H.; Stanley, C.A.; Thornton, P.S.; Clement, J.P.; Bryan, J.; Aguilar-Bryan, L.; Permutt, M.A. Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum. Mol. Genet. 1996, 5, 1813-1822.
29. Adelman, J.P.; Bond, C.T.; Pessia, M.; Maylie, J. Episodic ataxia results from voltage-dependent potassium channels with altered functions. Neuron 1995, 15, 1449-1454.
30. Lees-Miller, J.P.; Duan, Y.J.; Teng, G.Q.; Duff, H.J. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. 2000, 57, 367-374.
31. + channel-related long-QT syndrome: altered gating and selectivity in the HERG1 N629D mutant. Circ. Res. 2000, 86, 507-513.
32. Teng, G.Q., Zhao, X.; Cross, J.C.; Li, P.; Lees-Miller, J.P.; Guo, J.Q.; Dyck; J.R.B.; Duff, H.J. Prolonged repolarization and triggered activity induced by adenoviral expression of HERG N629D in cardiomyocytes derived from stem cells. Cardiovasc. Res. 2004, 61, 268-277.
33. Perry, M.; de Groot, M.J.; Helliwell, R.; Leishman, D.; TristaniFirouzi, M.; Sanguinetti, M.C.; Mitcheson, J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol. Pharmacol. 2004, 66, 240-249.
34. Sanguinetti, M.C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440, 463-469.
35. Flagg, T.P.; Nichols, C. Sarcolemmal KATP channels: What do we really know? J. Mol. Cell. Cardiol. 2005, 39, 61-70.
36. De Ponti, F.; Poluzzi, E.; Montanaro, N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. 2000, 56, 1-18.
37. Brown, A.M. Drugs, hERG and sudden death. Cell Calcium 2004, 35, 543-547.
38. Raschi, E.; Ceccarini, L.; De Ponti, F.; Recanatini, M. hERGrelated drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin. Drug Metab. Toxicol. 2009, 5, 1005-1021.
39. Redfern, W.S.; Carlsson, L.; Davis, A.S.; Lynch, W.G.; MacKenzie, I.; Palethorpe, S.; Siegl, P.K.S.; Strang, I.; Sullivan, A.T.; Wallis, R.; Camm, A.J.; Hammond, T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovas. Res. 2003, 58, 32-45.
40. Choe, H.; Nah, K.H.; Lee, S.N.; Lee, S.H.; Lee, S.H.; Jo, S.H.; Leem, C.H.; Jang, Y.J. A novel hypothesis for the binding mode of HERG channel blockers. Biochem. Biophys. Res. Comm. 2006, 344, 72-78.
41. Meyer, T.; Boven, E.G.; Fejtl, M. Micro-Electrode arrays (MEA) a novel tool in cardiac safety pharmacology to study QTprolongation. Drug Safety 2004, 27, 763-772.
42. Finlayson, K.; Turnbull, L.; January, C.T.; Sharkey, J.; Kelly, J.S. [3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur. J. Pharmacol. 2001, 430, 147-148.
43. Cheng, C.S.; Alderman, D.; Kwash, J.; Dessaint, J.; Patel, R.; Lescoe, M.K.; Kinrade, M.B.; Yu, W. A high-throughput HERG potassium channel function assay: An old assay with a new look. Drug Dev. Ind. Pharm. 2002, 28, 177-191.
44. Dorn, A.; Hermann, F.; Ebneth, A.; Bothmann, H.; Trube, G.; Christensen, K.; Apfel, C. Evaluation of a high-throughput fluorescence assay method for hERG potassium channel inhibition. J. Biomol. Screen. 2005, 10, 339-347.
45. Carlsson, L. Drug-induced torsade de pointes: the perspectives of industry. Eur. Heart J. Suppl. 2001, 3, K114-K120.
46. Gintant, G.A.; Limberis, J.T.; McDermott, J.S.; Wegner, C.D.; Cox, B.F. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 2001, 37, 607-618.
47. Hamlin, R.L.; Cruze, C.A.; Mittelstadt, S.W. et al. Sensitivity and specificity of isolated perfused guinea pig heart to test for druginduced lengthening of QTc. J. Pharmacol. Toxicol. Methods 2004, 49, 15-23.
48. Aubert, M.; Osterwalder, R.; Wagner, B. et al. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug torsades de pointes in humans. Drug Safety 2006, 29, 237254.
49. Lu, H.R.; Vlaminckx, E.; Van de Water, A. et al. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur. J. Pharmacol. 2006, 553, 229-239.
50. Cavero, I.; Yan, G.X.; Lux, R.; Steinhoff, U. Safety pharmacology and prolongation of the QT interval. J. Electrocardiol. 2007, 40, S58-S61.
51. Fehrst, A. Structure and mechanism in protein science. Freeman, New York, 1999.
52. Elcock, A.H.; Sept, D.; McCammon, J.A. Computer simulation of protein protein interactions. J. Phys. Chem. B. 2001, 105, 15041514.
53. Cianchetta, G.; Li, Y.; Kang, J.; Rampe, D.; Fravolini, A.; Cruciani, G.; Vaz, R.J. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett. 2005, 15, 3637-3642.
54. Norinder, U. In silico modelling of admet A minireview of work from 2000 to 2004. SAR QSAR Environ. Res. 2005, 16, 1-11.
55. Recanatini, M.; Cavalli, A.; Masetti, M. In silico modellingpharmacophores and hERG channel models. Novartis Found. Symp. 2005, 266, 171-181.
56. Aronov, A.M. Predictive in silico modeling for hERG channel blockers. Drug Discov. Today 2005, 10, 149-155.
57. Recanatini, M.; Cavalli, A.; Masetti, M. Modeling hERG and its interactions with drugs: Recent advances in light of current potassium channel simulations. ChemMedChem 2008, 3, 523-535.
58. rd ed.) Sunderland, 2001.
59. Armstrong, C. Voltage-Gated K channels. Sci. STKE 2003, 188 re10. [DOI: 10.1126/stke.2003.188.re10]
60. Ashcroft, F.M. From molecule to malady. Nature 2006, 7083,440-447.
61. Sigworth, F.J. Voltage gating of ion channels. Quart. Rev. Biophys. 1993, 27,1-40.
62. Sanguinetti, M.C.; Mitcheson, J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26, 119-124.
63. + channels. Physiol. Reviews 2005, 85, 33-47.
64. Guo, J.Q.; Zhan, S.; Lees-Miller J.P.; Teng, G.Q.; Duff, H.J. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37°C and 42°C. Heart Rhythm. 2005, 2, 860-866.
65. Perry, M, Stansfeld, P.J.; Leaney, J.; Wood, C.; De Groot, M.J.; Leishman, D. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol. Pharmacol. 2006, 69, 509-519.
66. Doyle, D.A.; Cabral, J.M.; Pfuetzner, R.A.; Kuo, A.; Gulbis, J.M.; Cohen, S.L.; Chait, B.T.; MacKinnon, R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998, 280, 69-77.
67. Zhou, Y.; Morais-Cabral, J.H.; Kaufman, A.; MacKinnon, R. Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 Å resolution. Nature 2001, 414, 43-48.
68. Jiang, Y.; Lee, A.; Cadene, M.; Chait, B.T.; MacKinnon, R. The open pore conformation of potassium channels. Nature 2002, 417, 523-526.
69. Jiang, Y.; Lee, A.; Chen, J.Y.; Ruta, V.; Cadene, M.; Chait, B.T.; MacKinnon R. X-ray structure of a voltage-dependent K+ channel. Nature 2003, 423, 33-41.
70. Jiang, Q.X.; Wang, D.N.; Mackinnon R. Electron microscopic analysis of KvAP voltagedependent K+ channels in an open conformation. Nature 2004, 430, 806-810.
71. Long, S.B.; Campbell, E.B.; MacKinnon, R. Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science 2005, 309, 903-908.
72. Long, S.B.; Campbell, E.B.; Mackinnon, R. Crystal structure of a mammalian voltagedependent Shaker family K+ channel. Science 2005, 309, 897-903.
73. Jan, L.; Jan, Y. Cloned potassium channels from eukaryotes and prokaryotes. Ann. Rev. Neurosci. 1997, 20, 91-123.
74. Vaz, R.J.; Klabunde, T.; Dalibalta, S.; Mitcheson, J.S. Eds. Antitargets: Methods and Principles in Medicinal Chemistry, hERG channel physiology and drug-binding structure-activity relationships: Chapter 4, 2008.
75. 2+-induced modification of human ether-à-go-go-related gene (hERG) channel activation. J. Physiol. (Lond.) 2005, 567, 737-755.
76. Viskin, S.; Justo, D.; Zeltser, D. Drug-induced prolongation of the QT interval. New Engl. J. Med. 2004, 350, 2618-2621.
77. Shantsila, E.; Watson, T.; Lip, G.Y.H. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 2007, 9, 37-44.
78. Shah, R. R. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann. Med. 2004, 36, 47-52.
79. Shah, R. R. Drug-induced prolongation of the QT interval: Why the regulatory concern? Fundam. Clin. Pharmacol. 2002, 16, 119-124.
80. Sanguinetti, M.C.; Bennett, P.B. Antiarrhythmic drug target choices and screening. Circ. Res. 2003, 93: 491-499.
81. Seebohm, G.; Chen. J., Strutz, N.; Culberson, C.; Lerche, C., et al. Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol. Pharmacol. 2003, 64, 70-77.
82. Rolf, S.; Haverkamp, W.; Borggrefe, M.; Musshoff, U.; Eckardt, L. et al. Effects of antiarrhythmic drugs on cloned cardiac voltagegated potassium channels expressed in Xenopus oocytes. NaunynSchmiedebergs Arch. Pharmacol. 2000, 362, 22-31.
83. Roden, D. M. Drug-Induced Prolongation of the QT Interval. New Engl. J. Med. 2004, 350, 1013-1022.
84. Perrin, M.J.; Kuchel, P.W.; Campbell, T.J.; Vandenberg, J.I. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol. Pharmacol. 2008, 74, 1443-1452.
85. Mitcheson, J.S.; Chen, L.; Lin, M.; Culberson, C.; Sanguinetti, M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. 2000, 97, 12329-12333.
86. Kiehn, J.; Lacerda, A.E.; Wible, B.; Brown, A.M. Molecular physiology and pharmacology of HERG: Single-channel currents and block by dofetilide. Circulation 1996, 94, 2572-2579.
87. Smith, P.L.; Baukrowitz, T.; Yellen, G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996, 379, 833-836.
88. Roepke, T.K.; Abbott, G.W. Pharmacogenetics and cardiac ion channels. Vasc. Pharmacol. Sci. 2006, 44, 90-106.
89. Fernandez, D.; Sargent, J.; Sachse, F. B.; Sanguinetti, M. C. Structural Basis for Ether-a-go-go-Related Gene K+ Channel SubtypeDependent Activation by Niflumic Acid. Mol. Pharmacol. 2008, 73, 1159-1167.
90. Du, L.; Li, M.; You, Q.; Xia, L. A novel structure-based virtual screening model for the hERG channel blockers. Biochem. Biophys. Res. Comm. 2007, 355, 889-894.
91. Gepp, M.M.; Hutter, M.C. Determination of hERG channel blockers using a decision tree. Bioorg. Med. Chem., 2006, 14, 5325-5332.
92. Abriel, H.; Schlapher, J.; Keller, D.I.; Gavillet, B.; Buclin, T.; Biollaz, J.; Stoller, R.; Kappenberger, L. Molecular and clinical determinants of drug-induced long QT syndrome: An iatrogenic channelopathy. Swiss Med. Wkly. 2004, 134, 685-694.
93. Nakajima, T.; Hayashi, K.; Viswanathan, P.C.; Kim, M.Y.; Anghelescu, M.; Barksdale, K.A.; Shuai, W.; Balser, J.R.; Kupershmidt, S. HERG is protected from pharmacological block by {alpha}-1,2-glucosyltransferase function. J. Biol. Chem. 2007, 282, 5506-5513.
94. + channel using docking and molecular dynamics methods. FEBS Lett. 2005, 579, 2939-2944.
95. Jalaie, M.; Holsworth, D.D. QT interval prolongation: And the beat goes on. Mini Rev. Med. Chem. 2005, 5, 1083-1091.
96. Rajamani, R.; Tounge, B.A.; Li, J.; Reynolds, C.H. A two-state homology model of the hERG K+ channel: Application to ligand binding. Bioorg. Med. Chem. Lett. 2005, 15, 1737-1741.
97. Tseng, G.N.; Sonawane, K.D., Korolkova, Y.V.; Zhang, M.; Liu, J. et al. Probing the outer mouth structure of the hERG channel with peptide toxin footprinting and molecular modeling. Biophys. J. 2007, 92, 3524-3540.
98. Kutteh, R.; Vandenberg, J.I.; Kuyucak, S. Molecular dynamics and continuum electrostatics studies of inactivation in the HERG potassium channel. J. Phys. Chem. B. 2007, 111, 1090-1098.
99. Stork, D.; Timin, E.N.; Berjukow, S.; Huber, C.; Hohaus, A.; Auer, M.; Hering, S. State dependent dissociation of HERG channel inhibitors. Br. J. Pharmacol. 2007, 151, 1368-1376.
100. Duan, J.J.; Ma, J.; Zhang, P.; Wang, X.; Zou, A.; Tu, D. Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol. Sin. 2007, 28, 959-967.
101. Calderone, V.; Testai, L.; Martinotti, E.; Del Tacca, M.; Breschi, M.C. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: The case of antipsychotics. J. Pharm. Pharmacol. 2005, 57, 151-161.
102. Malik, M. Detection of drug-induced proarrhythmia: Balancing preclinical and clinical studies. Heart Rthym 2005, 2, 773-776.
103. Cheng, L.; Kinard, K.; Rajamani, R.; Sanguinetti, M.C. Molecular mapping of the binding site for a blocker of hyperpolarizationactivated, cyclic nucleotide-modulated pacemaker channels. J. Pharmacol. Exp. Therap. 2007, 322, 931-939.
104. Jiang, Y.; Lee, A.; Chen, J.; Cadene, M.; Chait, B.T.; Mackinnon, R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002, 417, 515-522.
105. Jiang, Y.; Ruta, V.; Chen, J.; Lee, A.; Mackinnon R. Nature 2003, 423, 42-48.
106. Jogini, V.; Cuello, L.; Cortes, M.; Perozo, E. Biophys. J. 2008, Conference Abstract, P939.
107. Hardman, R.M.; Stansfeld, P.J.; Dalibalta, S.; Sutcliffe, M.J.; Mitcheson, J.S. Activation gating of hERG potassium channels: S6 glycines are not required as gating hinges. J. Biol. Chem. 2007, 282, 31972-31981.
108. Stary, A.; Wacker, S.J.; Boukharta, L.; Zachariae, L.; KarimiNejad, Y.; Åqvist, J.; Vriend, J.; De Groot, B. Toward a consensus model of the hERG potassium channel. ChemMedChem 2010, 5, 455-467.
109. Farid, R.; Day, T.; Friesner, R.A.; Pearlstein, R.A. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg. Med. Chem. 2006, 14, 3160-3173.
110. Pearlstein, R.A.; Vaz, R.J; Kang, J.; Chen, X.L.; Prebrazhenskaya, M.; Shchekotikhin, A.E.; Korolev, A.M.; Lysenkova, L.N.; Miroshnikova, O.V.; Hendrix, J.; Rampe, D. Characterization of HERG potassium channel inhibition using CoMSIA 3D QSAR and homology modeling approaches Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835.
111. Stansfeld, P.J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J.S. et al. Drug block of the hERG potassium channel: Insight from modeling. Proteins: Struct. Funct. Bioinform. 2007, 68, 568-580.
112. Yoshida, K.; Niwa, T. Quantitative structure-Activity relationship studies on inhibition of HERG potassium channels. J. Chem. Inf. Model. 2006, 46, 1371-1378.
113. Clarke, C.E.; Hill, A.P.; Zhao, J.; Kondo, M.; Subbiah, R.N.; Campbell, T.J.; Vandenberg, J.I. Effect of S5P -helix charge mutants on inactivation of hERG K+ channels. J. Physiol. 2006, 573, 291-304.
114. Fan, J.S.; Jiang, M.; Dun, W.; Mcdonald, T.V.; Tseng, G.N. ffects of outer mouth mutations on hERG channel function: A comparison with similar mutations in the Shaker channel. Biophys J. 1999, 76, 3128-3140.
115. Hill, A.P.; Sunde, M.; Campbell, T.J.; Vandenberg, J.I. Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys. J. 2007, 92, 3915-3929.
116. Jiang, M.; Zhang, M.; Maslennikov, I.V.; Liu, J.; Wu, D.M.; Korolkova, Y.V.; Arseniev, A.S.; Grishin, E.V.; Tseng, G.N. Dynamic conformational changes of extracellular S5-P linkers in the hERG channel. J. Physiol. London 2005, 569,75-89.
117. Ju, P.; Torres, A.M.; Bansal, P.S.; Kuchel, P.W.; Vandenberg, J.I. Pore helix domain charged residues modulate inactivation of the hERG K+ channel. Biophys. J. 2007, 123A-123A.
118. Lees-Miller, J.P.; Subbotina, J.O.; Guo, J.; Yarov-Yarovoy, V.; Noskov, S.Y. et al. Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function. Biophys. J. 2009, 96, 3600-3610.
119. Pathak, M.M.; Yarov-Yarovoy, V.; Agarwal, G.; Roux, B.; Barth, P.; Kohout, S.; Tombola, F.; Isacoff, E.Y. Closing in on the resting state of the shaker K+ channel. Neuron 2007, 56,124-140.
120. Yarov-Yarovoy, V.; Schonbrun, J.; Baker, D. Multipass membrane protein structure prediction using Rosetta. Proteins: Struct. Funct. Genet. 2006, 62, 1010-1025.
121. Yarov-Yarovoy, V. Baker, D.; Catterall, W.A. Voltage sensor conformations in the open and closed states in ROSETTA structural models of K+ channels. Proc. Natl. Acad. Sci. USA 2006, 103, 7292-7297.
122. Elofsson, A.; Von Heijne, G. Membrane protein structure: Prediction versus reality. Ann. Rev. Biochem. 2007, 76,125-140.
123. + channel. J. Biol. Chem. 2009, 284, 1000-1008.
124. + channel open-channel block by methanesulfonanilides. Circ. Res. 1996, 78, 499-503.
125. Witchel, H.J.; Dempsey, C.E.; Sessions, R.B.; Perry, M.; Milnes, J.T.; Hancox, J.C.; Mitcheson, J.S. The low-potency, voltagedependent herg blocker propafenone Molecular determinants and drug trapping. Mol. Pharmacol. 2004, 66, 1201-1212.
126. Barth, P.; Wallner, B.; Baker, D. Prediction of membrane protein structures with complex topologies using limited constraints. Proc. Natl. Acad. Sci. USA 2009 106(5), 1409-1414.
127. Rampe, D.; Wible, B.; Brown, A.M.; Dage, R.C. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol. Pharmacol. 1993, 44, 1240-1245.
128. Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M.C. Physicochemical features of the hERG channel drug binding site. J. Biol. Chem. 2004, 279, 10120-10127.
129. Chen, J.; Seebohm, G.; Sanguinetti, M.C. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci. 2002, 99, 12461-12466.
130. Meyers, K.M.; Mendez-Andino, J.L.; Colson, A.O.; Warshakoon, N.C.; Wos, J.A.; Mitchell, M.C.; Hodge, K.M.; Howard, J.M.; Ackley, D.C.; Holbert, J.K. Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists-Increasing selectivity over Herg. Bioorg. Med. Chem. Lett. 2007, 17, 814-818.
131. Magidovich, E.; Yifrach, O. Conserved gating hinge in ligandand voltage-dependent K+ channels. Biochemisty 2004, 43, 1324213247.
132. Kamiya, K.; Niwa, R.; Mitcheson, J.S.; Sanguinetti, M.C. Molecular determinants of hERG channel block. Mol. Pharmacol., 2006, 69, 1709-1716.
133. Thai, K.M.; Ecker, G.F. Predictive models for hERG channel blockers: Ligand-based and structure-based approaches. Curr. Med. Chem. 2007, 14, 3003-3026.
134. Milnes, J.T.; Crociani, O.; Arcangeli, A.; Hancox, J.C.; Witchel, H.J. Blockade of HERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. 2003, 139, 887-898.
135. Ridley, J.M.; Milnes, J.T.; Witchel, H.J.; Hancoux, J.C. High affinity HERG K channel blockade by the antiarrhythmic agent dronedarone: Resistance to mutations of the S6 residues Y652 and F656. Biochem. Biophys. Res. Commun. 2004, 325, 883-891.
136. Maggiora, G.M. On outliers and activity cliffs Why QSAR often disappoints. J. Chem. Inf. Model. 2006, 46, 1535.
137. Jamieson, C.; Moir, E.M; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: highlights and hang-ups. J. Med. Chem. 2006, 49, 5029-5046.
138. Carmeliet, E. Voltageand time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J. Pharmacol. Exp.Ther. 1992, 262, 809-817.
139. Armstrong, C.M. Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J. Gen. Physiol. 1971, 58, 413-437.
140. Ekins, S.; Crumb, W.J.; Sarazan, R.D.; Wikel, J.H.; Wrighton, S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 301, 427-434.
141. Shamovsky, I.; Connolly, S.; David, L.; Ivanova, S.; Norden, B.; Springthorpe, B.; Urbahns, K. Overcoming undesirable hERG potency of chemokine receptor antagonists using baseline lipophilicity relationships. J. Med. Chem. 2008, 51, 1162-1178.
142. Free, S.M. Jr.; Wilson, J.W. A mathematical contribution to structure-activity studies. J. Med. Chem. 1964, 7, 395-399.
143. Perry, M.; Sachse, F.B.; Sanguinetti, M.C. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc. Natl. Acad. Sci. 2007, 104, 13827-13832.
144. Casis, O.; Olesan, S.P.; Sanguinetti, M.C. Mechanism of action of a novel human ether-a-go-go-related gene channel activator Mol. Pharmacol. 2006, 69, 658-665.
145. Kang, J.; Chen, X.L.; Wang, H.; Ji, J.; Cheng, H.; Incardona, J.; Reynolds, W.; Viviani, F.; Tabart, M.; Rampe, D. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol. Pharmacol. 2005, 67, 827-836.
146. Hansen, R.S.; Diness, T.G.; Christ, T.; Wettwer, E.; Ravens, U.; Olesen, S.P.; Grunnet, M. Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 N-(4bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl) urea. Mol. Pharmacol. 2006, 70, 1319-1329.
147. Su, Z.; Limberis, J.; Souers, A.; Kym, P.; Mikhail, A.; Houseman, K.; Diaz, G.; Liu, X.; Martin, R.L.; Cox, B.F.; Gintani, G.A. Electrophysiologic characterization of a novel hERG channel activator. Biochem. Pharmacol. 2009, 77, 1383-1390.
148. Xu, X.; Recanatini, M.; Roberti, M.; Tseng, G.N. Probing the binding sites and mechanisms of action of two human ether-a-go-gorelated gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243). Mol. Pharmacol. 2008, 73, 1709-1721.
149. Zhou, J.; Augelli-Szafran, C.E.; Bradley, J.A.; Chen, X.; Koci, B.J.; Volberg, W.A.; Sun, Z.; Cordes, J.S. Novel potent human ether-àgo-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. 2005, 68, 876884.
150. Zeng, H.; Lozinskaya, I.M.; Lin, Z.; Willete, R.N.; Brooks, D.P; Xu, X. Mallotoxin is a novel human Ether-a-go-go-related gene (hERG) potassium channel activator. J. Pharmcol. Exp. Ther. 2006, 319, 957-962.
151. Gordon, E.; Lozinskaya, I.M.; Lin, Z.; Semus, SF.; Blaney, F.E.; Willete, R.N.; et al. 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1Hisoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-gorelated gene potassium channels. Mol. Pharmacol. 2008, 73, 639-651.
152. Nattel, S.; Carlsson, L. Innovative approaches to anti-arrhythmic drug therapy. Nat. Rev. Drug. Discov. 2006, 5, 1034-1049.
153. Gandhi, C.S.; Clark, E.; Loots, E.; Pralle, A.; Isacoff, E.Y. The orientation and molecular movement of a K+ channel voltagesensing domain. Neuron 2003, 40, 515-525.
154. Waring, M.J.; Johnstone, C.A. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764.
155. Long, S.B.; Tao, X.; Campbell, E.B.; MacKinnon, R. Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment. Nature 2007, 450, 376382.
156. Stahl, M.; Rarey, M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem. 2001, 44, 1035-1042.
157. Barth, P.; Wallner, B.; Baker, D. Prediction of membrane protein structures with complex topologies using limited constraints. Proc. Natl. Acad. Sci. USA. 2009, 106(5), 1409-1414.
158. Jogini, V.; Roux, B. Dynamics of the Kv1.2 voltage-gated K+ channel in a membrane environment. Biophys. J. 2007, 93, 30703082.
159. Noskov, S.Y.; Berneche, S.; Roux, B. Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands. Nature 2004, 431, 830-834.
160. Khalili-Araghi, F.; Tajkhorshid, E.; Schulten, K. Calculation of the gating charge for the Kv1.2 voltage-activated potassium channel. Biophys. J. 2006, 91, L2-L4.
161. Recanatini, M.; Poluzzi, E.; Masetti, M.; Cavalli, A.; De Ponti, F. QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 2005, 25, 133-166.
162. Subbotina, J.; Yarov-Yarovoy, V.; Lees-Miller, J.; Durdagi, S.; Guo, J.; Duff, H.J. Noskov S.Y. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTAmembrane and molecular dynamics simulations. Proteins: Struct. Funct. Bioinform. 2010, (in press).
163. + channel blockers. J. Med. Chem. 2002, 45, 3844-3853.
164. Roche, O.; Trube, G.; Zuegge, J.; Pflimlin, P.; Alanine, A.; Schenider, G. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. ChemBioChem 2002, 3, 455-459.
165. Bains, W.; Basman, A.; White, C. HERG binding specificity and binding site structure: Evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol. 2004, 86, 205-233.
166. Aronov, A.M.; Goldman, B.B. A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem. 2004, 12, 2307-2315.
167. Zolotoy, A.B.; Plouvier, B.P.; Beatch, G.B.; Hayes, E.S.; Wall, R.A.; Walker, M.J. Physicochemical determinants for drug induced blockade of HERG potassium channels: effect of charge and charge shielding. Curr. Med. Chem. Cardiovasc. Hamatol. Agents 2003, 1, 225-241.
168. Johnson, S.R.; Yue, H.; Conder, M.L.; Shi, H.; Doweyko, A.M.; Lloyd, J.; Levesque, P. Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR. Bioorg. Med. Chem. 2007, 15, 6182-6192.
169. Keseru, G.M. Prediction of hERG potassium channel affinity by traditional and hologram QSAR methods. Bioorg. Med. Chem. Lett. 2003, 13, 2773-2775.
170. Tobita, M.; Nishikawa, T.; Nagashima, R. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2886-2890.
171. Sun, H. An accurate and interpretable bayesian classification model for prediction of HERG liability. ChemMedChem 2006, 1, 315-322.
172. Song, M.; Clark, M. Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model. 2006, 46, 392-400.
173. Durdagi, S.; Duff, H.J.; Noskov, S.Y. unpublished work (article in preparation).
174. Jamieson, C.; Moir, E.M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 2006, 49, 5029-5046.
175. Ulens, C.; Daenens, P.; Tytgat, J. Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc. Res., 1999, 44, 568-578.
176. Dennis, A.; Wang, L.; Wan, X.; Ficker, E. hERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochem. Soc. Trans., 2007, 35, 1060-1063.
177. Eckhardt, L.L.; Rajamani, S.; January, C.T. Protein trafficking abnormalities: A new mechanism in drug-induced long QT syndrome. Br. J. Pharmacol. 2005, 145, 3-4.
178. van der Heyden, M.A.; Smits, M.E.; Vos, M.A. Drugs and trafficking of ion channels: A new pro-arrhythmic threat on the horizon? Br. J. Pharmacol. 2008, 153, 406-409.
179. Rajamani, S.; Eckhardt, L.L.; Valdivia, C.R.; Klemens, C.A.; Gillman, B.M.; Anderson, C.L.; Holzem, K.M.; Delisle, B.P.; Anson, B.D.; Makielski, J.C.; January, C.T. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br. J. Pharmacol. 2006, 149, 481-489.